A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia

Blood

Volumn 103, Issue 12, 2004, Pages 4659-4665

  Willmore, Elaine ^b   De Caux, Sarah ^b   Sunter, Nicola J ^b   Tilby, Michael J ^b   Jackson, Graham H ^b   Austin, Caroline A ^b   Durkacz, Barbara W ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CAMPTOTHECIN; CYTARABINE; DNA DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; NU 7026; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; NONHOMOLOGOUS END JOINING; PRIORITY JOURNAL;

EID: 2942591949     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2527     Document Type: Article

References (47)

1. Lichtman MA, Liesveld JL. Acute myelogenous leukemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Haematology. New York, McGraw-Hill; 2002:1047-1081.
2. Nussler V, Pelka-Fleischer R, Zwierzina H, et al. p-Glycoprotein expression in patients with acute leukemia-clinical relevance. Leukemia. 1996;10:23-31.
3. Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol Res. 1996;8:229-238.
4. Fernandes DJ, Qiu J, Catapano CV. DNA topoisomerase II isozymes involved in anticancer drug action and resistance. Adv Enzyme Regul. 1995;35:265-281.
5. Albertioni F, Gruber A, Arestrom I, Vitols S. Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Medical Oncol. 1995;12:79-86.
6. Austin CA,Marsh KL. Eukaryotic DNA topoisomerase II beta. Bioessays. 1998;20:215-226.
7. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002;3:235-243.
8. Jackson SP. Sensing and repairing DNA double strand breaks. Carcinogenesis. 2002;23:687-696.
9. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol. 2001;13:225-231.
10. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev. 1999;13:916-934.
11. Caldecott J, Jeggo P. Cross sensitivity of gamma ray-sensitive hamster mutants to cross-linking agents. Mutat Res. 1991;255:111-121.
12. Tanaka T, Yamagami T, Oka Y, Nomura T, Sugiyama H. The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutat Res. 1993;288:277-280.
13. Gu Y, Jin S, Gao Y, Weaver DT, Frederick W. Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination. Proc Natl Acad Sci U S A. 1997;94:8076-8081.
14. Critchlow SE, Jackson SP. DNA end joining: from yeast to man. Trends Biochem Sci. 1998;23:394-398.
15. Pannicke MY, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell. 2002;108:781-794.
16. DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ Jr, Iliakis G. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res. 2000;60:1245-1253.
17. Jeggo PA, Caldecott K, Pidsley S, Banks GR. Sensitivity of Chinese hamster ovary mutants defective in DNA repair to topoisomerase II inhibitors. Cancer Res. 1989;49:7057-7063.
18. Caldecott K, Banks G, Jeggo P. DNA double strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res. 1990;50:5778-5783.
19. He DM, Lee SE, Hendrickson EA. Restoration of X-ray and etoposide resistance, Ku-end binding activity and V(D)J recombination to the Chinese hamster sxi-3 mutant by a hamster Ku86 cDNA. Mutat Res. 1996;363:43-56.
20. Izzard RA, Jackson SP, Smith GCM. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 1999;59:2581-2586.
21. Boulton S, Kyle S, Yalçintepe L, Durkacz BW. Wortmannin is a potent inhibitor of DNA double strand break repair but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis. 1996;17:2285-2290.
22. Rosenzweig KE, Youmell MB, Palayoor ST, Price BR. Radiosensitization of human tumor cells by the phosphatidyl inositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res. 1997;3:1149-1156.
23. Boulton S, Kyle S, Durkacz BW. Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation treated cells by the protein kinase inhibitor wortmannin. Eur J Cancer. 2000;36:535-541.
24. Veuger SJ, Curtin, NJ, Richardson, CJ, Smith GC, Durkacz, BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003;63:6008-6015.
25. Willmore E, Frank AJ, Padget K, Tilby MJ, Austin CA. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol. 1998;54:78-85.
26. Bradley MO, Kohn KW. X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution. Nucleic Acids Res. 1979;7:793-804.
27. Fornace AJ Jr, Little JB. DNA crosslinking induced by X-rays and chemical agents. Biochim Biophys Acta. 1977;477:343-355.
28. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev. 2001;11:71-77.
29. Errington F, Willmore E, Tilby MJ, et al. Murine transgenic cells lacking DNA topoisomerase II-beta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol. 1999;56:1309-1316.
30. Willmore E, Errington, F, Tilby MJ, Austin CA. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem Pharmacol. 2002;63:1807-1815.
31. Pommier Y, Leteutre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12:530-542.
32. Capranico G, Soranzo C, Zunino F. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res. 1986;46:5499-5503.
33. Binaschi M, Capranico G, De Isabella P, et al. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer. 1990;45:347-352.
34. Martensson S, Nygren J, Osheroff N, Hammarsten O. Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiat Res. 2003;160:291-301.
35. Yang SW, Burgin AB Jr, Huizenga BN, Robertson CA, Yao KC, Nash HA. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci U S A. 1996;93:11534-11539.
36. Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1998;1400:257-274.
37. Xu W, Liu L, Smith GCM, Charles IG. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol. 2000;2:329-345.
38. Muller C, Chistodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood. 1998;92:2213-2219.
39. Sirzen F, Nilsson A, Zhivotovsky B, Lewensohn R. DNA-dependent protein kinase content and activity in lung carcinoma cell lines; correlation with intrinsic radiosensitivity. Eur J Cancer. 1999;35:111-116.
40. Muller C, Calsou P, Salles B. The activity of the DNA-dependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards. Biochimie. 2000;82:25-28.
41. Tew KD, O'Brien M, Laing NM, Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact. 1998;111-112:199-211.
42. Eriksson A, Lewensoh R, Larsson R, Nilsson A. DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res. 2002;22:1787-1793.
43. Sak A, Stuschke M, Wurm R, et al. Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA doublestrand breaks and radiosensitivity of human cancer cell lines. Cancer Res. 2002;62:6621-6624.
44. Peng Y, Zhang, Q, Nagasawa H, Okasayu R, Liber HL, Bedford JS. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing and mutation. Cancer Res. 2002;62:6400-6404.
45. Kim C-H, Park S-J, Lee S-H. A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther. 2002;303:753-759.
46. Omori S, Takiguchi Y, Suda A, et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio-and chemosensitivity in a human lung carcinoma cell line. DNA Repair. 2002;1:299-310.
47. Spencer CJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003;63:1550-1554.